Back to news

Jazz Pharmaceuticals Falls as Traders Weigh Minor Target Cut and Recent Insider-Sale Filings

Investivoq PriceTracker

Jazz Pharmaceuticals (JAZZ) is down 4.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The catalyst is not completely clear, but the drop appears tied to a softer analyst price-target revision and fresh insider-sale disclosures rather than a major new operational setback. This could also be a broader biotech pullback after a strong run earlier this year, especially since Jazz recently added positive regulatory and pipeline milestones.

Details:

  • A brokerage note published today trimmed its price target on Jazz to $296 from $299 while keeping a positive rating, which may have pressured sentiment even though the change was small.
  • SEC filings this week showed Chief Executive Bruce Cozadd sold 6,000 ordinary shares on October 1, 2026, and President and CEO Renee Gala sold 2,000 ordinary shares on October 6, 2026; both filings said the trades were made under Rule 10b5-1 trading plans.
  • Jazz disclosed on August 25, 2026 that the FDA approved new first-line gastroesophageal adenocarcinoma uses for Ziihera, so today’s decline does not appear to be driven by a fresh approval setback.
  • The company also completed its acquisition of Actio Biosciences in September and repriced and extended a term loan later that month, leaving room for investors to reassess integration, leverage, and valuation after a busy stretch of corporate activity.

    • Sources:

    SEC, Jazz Pharmaceuticals, MarketScreener

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $JAZZ Insider Trading Activity

    JAZZ Insider Trades

    $JAZZ insiders have traded $JAZZ stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.

    Here’s a breakdown of recent trading of $JAZZ stock by insiders over the last 6 months:

    • ROBERT IANNONE (EVP, Global Head of R&D & CMO) has made 0 purchases and 6 sales selling 76,921 shares for an estimated $19,207,097.
    • BRUCE C COZADD has made 0 purchases and 5 sales selling 30,000 shares for an estimated $6,973,380.
    • SAMANTHA PEARCE (EVP, Chief Commercial Officer) sold 6,907 shares for an estimated $1,625,976
    • RENEE D GALA (President & CEO) has made 0 purchases and 2 sales selling 4,000 shares for an estimated $958,860.
    • RICK E WINNINGHAM sold 2,741 shares for an estimated $662,143
    • NEENA M PATIL (EVP & Chief Legal Officer) has made 0 purchases and 2 sales selling 2,392 shares for an estimated $571,596.
    • HEATHER ANN MCSHARRY sold 2,000 shares for an estimated $482,000
    • MARK DOUGLAS SMITH sold 1,157 shares for an estimated $266,746

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive JAZZ Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $JAZZ Hedge Fund Activity

    We have seen 346 institutional investors add shares of $JAZZ stock to their portfolio, and 238 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • FMR LLC added 2,333,564 shares (+102.5%) to their portfolio in Q2 2026, for an estimated $562,318,917
    • ECOR1 CAPITAL, LLC removed 1,706,469 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $411,207,834
    • JPMORGAN CHASE & CO added 1,160,786 shares (+inf%) to their portfolio in Q2 2026, for an estimated $279,714,602
    • NORGES BANK added 656,843 shares (+inf%) to their portfolio in Q2 2026, for an estimated $158,279,457
    • HOLOCENE ADVISORS, LP removed 572,914 shares (-78.1%) from their portfolio in Q2 2026, for an estimated $138,055,086
    • MARINER, LLC added 568,599 shares (+1420.9%) to their portfolio in Q2 2026, for an estimated $137,015,301
    • MILLENNIUM MANAGEMENT LLC removed 498,631 shares (-39.5%) from their portfolio in Q2 2026, for an estimated $120,155,112

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $JAZZ Price Targets

    Multiple analysts have issued price targets for $JAZZ recently. We have seen 11 analysts offer price targets for $JAZZ in the last 6 months, with a median target of $265.0.

    Here are some recent targets:

    • Gregg Gilbert from Deutsche Bank set a target price of $270.0 on 07/09/2026
    • Gregory Renza from Truist Securities set a target price of $254.0 on 07/07/2026
    • Jason Gerberry from B of A Securities set a target price of $307.0 on 06/10/2026
    • Etzer Darout from Barclays set a target price of $253.0 on 05/27/2026
    • Jeffrey Walch from Bernstein set a target price of $229.0 on 05/22/2026
    • David Amsellem from Piper Sandler set a target price of $301.0 on 05/22/2026
    • Ashwani Verma from UBS set a target price of $307.0 on 05/19/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.